Combined treatment with two cancer immunotherapy drugs – one a novel immune modulator and one that focuses and activates the antitumor immune response – significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma. In their report published in Cancer Immunology Research, a team from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH)…